Filing Flows

Filing Flows › Myriad Genetics (MYGN) › Next earnings date

Myriad Genetics (MYGN) earnings: beat the estimate

Myriad Genetics (MYGN) reported on Nov 4, 2026 and beat the EPS estimate: −$0.11 against −$0.20 (+44.9%). Revenue was $203M for Q3 2026, -2% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+44.9% vs estimate
Beat rate60%

The last report

Myriad Genetics reported revenue of $203M for the third quarter 2026 (-2% Y/Y), net loss $43.9M: Cancer Care Continuum $124M, Mental Health $39.5M, Prenatal Health $39.3M. How it makes money → · Every quarter →

Myriad Genetics: EPS against the estimate, last 5 reportsMyriad Genetics: EPS against the estimate, last 5 reportsEstimateReported−$0.01$0.00Nov 25−$0.02$0.04Feb 26−$0.07−$0.09May 26−$0.06−$0.25Jul 26−$0.20−$0.11Nov 26
Latest (Nov 26): Estimate −$0.20, Reported −$0.11.

Myriad Genetics' latest quarter

Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did Myriad Genetics beat earnings?

Myriad Genetics (MYGN) reported on Nov 4, 2026 and beat the EPS estimate: −$0.11 against −$0.20 (+44.9%).

When does MYGN report earnings?

The next date is not set yet.

Does Myriad Genetics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.